Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
NCT06860529Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 2, randomised trial of serplulimab in breast cancer (3 arms), sponsored by Henan Cancer Hospital. Primary endpoints: Pathological Complete Response rate and Pathological Complete Response rate in PD-L1 positive subgroup. Started Apr 2025; status: recruiting.
02
Drugs
serplulimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06860529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860529.